Nephrogen vs Solv Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 preclinical gene therapy for polycystic kidney disease (600K US patients) using AI-driven target identification; $1.1M raised with NIH SBIR grant, raising $4M seed competing with CRISPR Therapeutics for curative kidney genetic medicine.
About
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
Solv Health is a same-day appointment booking platform for urgent care, primary care, and telehealth, offering patients transparent wait times and insurance-aware scheduling.
About
Solv Health operates a consumer-facing booking platform that aggregates same-day availability from urgent care centers, primary care practices, and telehealth providers — giving patients the ability to find and book immediate care without calling multiple clinics or waiting in walk-in lines. The platform displays real-time wait times, insurance acceptance, and directions, making the experience of finding immediate care as simple as booking a restaurant reservation.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.